Is CareDx, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for CareDx, Inc. moved from fair to very attractive, indicating a significant improvement in its valuation outlook. The company appears undervalued, particularly given its Price to Book Value of 2.87 and an EV to Sales ratio of 2.49, despite the negative P/E and ROE figures. CareDx's EV to EBIT stands at -27.94, which reflects its current loss-making status but also highlights potential for future recovery.
In comparison to its peers, CareDx's valuation metrics are notably more favorable, especially when contrasted with Organogenesis Holdings, Inc., which has a P/E ratio of 608.59, and Castle Biosciences, Inc., with an EV to EBITDA of -71.36. While CareDx has not provided multi-period return data, the overall market sentiment indicates a potential upside as it continues to navigate its challenges.